Variables | 296 patients |
---|---|
Age (years) | 62 (53–70) |
Male gender | 196 (66 %) |
Underlying malignancies | |
Hematologic malignancies | 242 (81.7 %) |
Acute leukemia | 99 (33.4 %) |
Lymphoma | 96 (32.4 %) |
Multiple myeloma | 28 (9.4 %) |
Miscellaneous | 19 (6.4 %) |
Solid tumors | 54 (18.3 %) |
Uro-genital | 17 (5.7 %) |
Digestive | 15 (5 %) |
Pulmonary | 9 (3 %) |
Breast | 6 (2 %) |
Bone and cartilage | 4 (1.3 %) |
Head and neck | 4 (1.3 %) |
Hematopoietic stem cell transplantation | 42 (14.2 %) |
Other comorbidities | |
Chronic heart failure | 61 (20.6 %) |
Chronic liver disease | 13 (4.4 %) |
Chronic and end-stage renal failure | 13 (4.4 %) |
Human immunodeficiency virus infection | 6 (2 %) |
Solid organ transplantation | 1 (0.3 %) |
Anticoagulant and antiplatelet medications | 69 (23.3 %) |
Prophylactic anticoagulant | 21 (7.1 %) |
Curative anticoagulant | 27 (9.1 %) |
Antiplatelet | 21 (7.1 %) |
Mechanisms of central thrombocytopenia | |
Chemo- or radiotherapy-induced | 223 (75.3 %) |
Bone marrow infiltration by malignant cells | 55 (18.5 %) |
Hemophagocytosis | 10 (3.4 %) |
Drug-induced (allergic) | 4 (1.3 %) |
Myelofibrosis | 4 (1.3 %) |